Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials

News
Article

Sponsored Content

The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.

Related Content
© 2024 MJH Life Sciences

All rights reserved.